The U.S. FDA has accepted a supplemental New Drug Application for Jardiance tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease, Boehringer Ingelheim and Eli Lilly and Company announced.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
- Eli Lilly (NYSE:LLY) Faces Setback in Alzheimer’s Drug Approval
- Eli Lilly discloses FDA complete response letter for submission of donanemab
- California AG files suit against drugmakers, PBMs over insulin prices
- Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
